Skip to main content

Longeveron Inc.

corporate_fare Company Profile

Longeveron Inc.

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 1 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer's disease, as well as in phase 2b clinical trial to treat aging frailty. The company was incorporated in 2014 and is headquartered in Miami, Florida.

Exchange: NASDAQSector: Life Sciences

show_chartPrice Chart

Loading chart...

feed LGVN - Latest Insights

LGVN
Apr 17, 2026, 4:23 PM EDT
Filing Type: 424B3
Importance Score:
9
LGVN
Apr 10, 2026, 4:55 PM EDT
Source: Reuters
Importance Score:
8
LGVN
Apr 10, 2026, 4:49 PM EDT
Filing Type: 8-K
Importance Score:
8
LGVN
Apr 10, 2026, 4:01 PM EDT
Filing Type: S-1
Importance Score:
9
LGVN
Mar 25, 2026, 4:00 PM EDT
Filing Type: 8-K
Importance Score:
7
LGVN
Mar 17, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
7
LGVN
Mar 17, 2026, 4:01 PM EDT
Filing Type: 10-K
Importance Score:
9
LGVN
Mar 12, 2026, 4:13 PM EDT
Source: Wiseek News
Importance Score:
9
LGVN
Mar 12, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
9
LGVN
Mar 11, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
8
LGVN
Mar 10, 2026, 9:02 AM EDT
Source: Dow Jones Newswires
Importance Score:
9
LGVN
Mar 09, 2026, 6:03 AM EDT
Source: Wiseek News
Importance Score:
8
LGVN
Mar 06, 2026, 5:59 PM EST
Filing Type: 8-K
Importance Score:
8
LGVN
Mar 03, 2026, 7:59 AM EST
Filing Type: PRE 14A
Importance Score:
8
LGVN
Feb 13, 2026, 4:45 PM EST
Filing Type: 8-K
Importance Score:
8